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A B S T R A C T
Background: Psoriasis is a chronic, inflammatory skin disorder resulting from a complex interplay
between immune and skin cells via release of soluble mediators. While a lot is known about the
molecular mechanisms behind psoriasis pathogenesis, there is still a need for preclinical research models
that accuratelyreplicate the disease.
Objective: This study aimed to develop and characterize ex vivo culture of psoriasis skin as a model for
pharmacological testing, where the immunological events of psoriasis can be followed.
Methods: Full thickness punch biopsies of lesional psoriasis skin were cultured in submerged conditions
up to 144 h followingin situ T cell stimulation with rhIL-23 and anti-CD3 and anti-CD28 antibodies. The
T cell mediated skin inflammation was assessed by gene and protein l analysis for a panel of inflammatory
mediators. Tissue integrity and morphology were evaluated by histological analysis.
Results: T cell stimulation resulted in functional and psoriasis specificin situ activation of T cells. The
expression levels of most of the proinflammatory mediators related to both immune and skin cells were
comparable to these in freshly isolated tissue at 48 and 96 h of culture. Tissue integrity and morphology
were sustained up to 96 h. Treatment with a corticosteroid reduced the expression of several pro-
inflammatory cytokines and chemokines, whereas anti-IL-17A antibody treatment reduced the
expression of the IL-17A downstream markers IL-8 and DEFB4.
Conclusion: By preserving keyimmunopathological mechanisms of psoriasis, ex vivo culture of psoriasis
skin can be used for the investigation of inflammatory processes of psoriasis and for preclinical drug
discovery research.
© 2020 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative
Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Psoriasis is a common, chronic T cell mediated skin disease
associated with several comorbidities and a low quality of life,
affecting 0.09–5.1 % of the population worldwide with significant
geographical differences in the prevalence [1]. The IL-23/Th17Abbreviations: DC, dendritic cell; IL-, interleukin-; Th, cell T helper cell; TNF,
tumor necrosis factor; IFN-g, interferon-g; CCL-20, chemokine (C-C motif) ligand-
20; hBD2, human beta defensin 2; HSE, human skin equivalent; DMSO, dimethyl
sulfoxide; ELISA, enzyme linked immunosorbent assay; IHC, immunohistochemi-
cal; DAB, diaminobenzidine; Abs, antibodies; K16, keratin 16; BDP, betamethasone
dipropionate; HE, Hematoxylin and eosin.
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(M.L. Tiirikainen), awoetmann@sund.ku.dk (A. Woetmann),
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(L.F. Santamaria-Babí), paldk@leo-pharma.com (P. Lovato).
https://doi.org/10.1016/j.jdermsci.2019.12.010
0923-1811/ © 2020 The Authors. Published by Elsevier B.V. on behalf of Japanese Society 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).immune axis plays a key role in the immunopathogenesis of the
disease; inflammatory dendritic cells (DCs) secrete interleukin
(IL)-23, which is essential for T helper (Th)17 cell differentiation
and sustained IL-17A secreting capacity [2]. Th17 derived
cytokines, IL-17A, IL-17A/F and IL-17F are the key drivers of the
activation, hyperproliferation and abnormal differentiation of
keratinocytes giving rise to the histopathological features of
psoriasis including hyperplasia, elongated rete ridges, and para-
keratosis. Further, other pro-inflammatory cytokines like tumor
necrosis factor (TNF)-α, IL-22 and interferon (IFN)-g also contrib-
ute to the epidermal inflammation [3]. Subsequently, the release of
inflammatory mediators like IL-8, and chemokine (C-C motif)
ligand-20 (CCL-20) by the activated keratinocytes results in
recruitment of additional immune cells [4].
To investigate the immune inflammatory processes and new
anti-inflammatory treatments with different mechanisms of
action, there is a need for translational preclinical models, which
can replicate the immunopathogenic mechanisms of the disease.for Investigative Dermatology. This is an open access article under the CC BY-NC-ND
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mononuclear cells and/or psoriatic skin grafts using lesional or
non-lesional skin are the in vivo models bearing closest resem-
blance to the immunopathogenesis of psoriasis [5,6]. However, the
T cell activity has been observed to gradually decline in the grafts
during the experimental period [7], and the human immune cells
may not be able to establish cross talk with the murine host cells
given the cross species differences [8]. As an alternative to animal
models, different skin explant models with healthy human skin
and human skin equivalent (HSE) models have been developed for
psoriasis [9]. The major challenges of these models are associated
with incorporation of immune cells of specific phenotype of
relevance in psoriasis, as well as with replicating the histopatho-
logical features of psoriasis [9]. Short term (1214 hrs) ex vivo
culture of psoriasis skin for test of anti-inflammatory compounds
has previously been reported by others, but a characterization of
the psoriasis phenotype upon ex vivo culture has not been included
[10,11].
To overcome the limitations of the above mentioned models,
we have also previously employed ex vivo culture of psoriatic
keratome biopsies [12]. Briefly, the key cellular activities and
inflammatory features as found in psoriatic skin in vivo were
resumed in the keratome biopsies by in situ activation of T cells and
maintained for up to 72 h. However, limitations of this model were
short culture time due to rapid loss of tissue integrity and limited
amount of dermis. Based on learnings from this model, we further
developed an ex vivo culture of psoriasis skin using full-thickness
biopsies, where the complex immunopathological events of
psoriasis are even better maintained, and which can be modulated
by pharmacological intervention.
2. Materials and methods
2.1. Human specimens
Full thickness punch biopsies, 5 mm of diameter, were obtained
from active lesions of untreated patients with psoriasis vulgaris
after approval from local ethical committees and the Danish Data
Protection Agency and upon written informed consent by the
patients. For each patient, a maximum of 6–7 adjacent biopsies
were taken from the center of the same active lesion. The biopsies
were either immediately snap frozen or fixed in formalin for
protein and histological analysis, respectively, or were transported
in cold Dulbecco’s modified Eagle medium containing 100 mg/ml
gentamicin, 100 U/ml penicillin, 100 mg/ml streptomycin and 2.5 m
g/ml Fungizone (All from Gibco, Life Technologies, Carlsbad, CA,
USA) up to arrival in the laboratory.
2.2. Psoriasis skin explant culture
The biopsies were placed in culture within maximum 30 h after
removal from the patient. The punch biopsies were cut in half and
each half served as an individual sample. The tissue was cultured in
24-well plates in 800 ml of EpiLife medium with 10 ng/ml rhIL-2
(Gibco, Life Technologies, Carlsbad, CA, USA), growth supplements
and antibiotics. For in situ activation of T cells, 1 mg/ml anti-CD3
(Cat:MAB100) and anti-CD28 (Cat: MAB342) antibodies or Mouse
IgG1 Isotype Control (Cat: MAB002), and 50 ng/ml rhIL-23
(Cat:1290-IL) (all from R&D Systems, Minneapolis, MN, USA) were
used. The biopsies were cultured either for 2, 5, 15, 24, 48, 96 or
144 h. Following ex vivo culture, the tissue samples and culture
supernatants were harvested and stored at 80 C or fixed in 4 %
formaldehyde until analysis. A schematic representation of the
study design (Figure S1) and a more detailed description of culture
conditions are included in the supplementary materials.2.3. Test compounds
For treatment with corticosteroid, the samples were treated at
thestartof theculturewitheither1mM betamethasonedipropionate
(BDP), or matching vehicle control (0.1 % dimethyl sulfoxide) for 48 h
or 96 h. Stock solution (10 mM) of BDP (provided by LEO Pharma A/S)
was prepared in dimethyl sulfoxide (DMSO) (Sigma–Aldrich,
St. Louis, MO, USA). The stock solution was diluted in tissue culture
mediumatthetime ofusetothe final concentrationof1mM.Thefinal
concentration used in this study is based on exposure data in human
skin after topical application of calcipotriol/betamethasone fixed-
combination product, as previously reported [12]. For treatment
with antibody, the samples were treated at the start of culture with
eitheranti-IL-17A antibody, oran isotype control, for 48 or 96 h. Anti-
human IL-17A antibody (Cat: AF-317-NA, R&D Systems Minneapolis,
MN, USA) was diluted in culture medium at the time of use to a final
concentration of 40 mg/ml. The final concentration used in this study
is based on the neutralization dose (ND50) of the neutralising
antibody reported by the manufacturer and chosen to be 300-fold
higher than the expected levels of IL-17A in the skin samples to
ensure a complete neutralization of IL-17A. For isotype control a
polyclonal goat IgG (Cat: AB-108-C, R&D Systems, Minneapolis,
MN, USA) was used.
2.4. Histology
The biopsies were fixed in 4 % formaldehyde for 2448 h at
room temperature prior paraffin embedding. Sections (4 mm) were
stained with hematoxylin and eosin (HE) for analysis of tissue
integrity.
2.4.1. Immunohistochemistry (IHC)
Sections (3 mm) were used for IHC staining. IHC was performed
following standard staining methods with minor variations on an
automated Leica Bond platform (BOND RX Fully Automated
Research Stainer, Leica Biosystems Nussloch GmbH, Germany).
Stimulating antibodies (anti-human CD3 and CD28 antibodies)
were detected with BOND Polymer Refine Detection (Cat: DS9800,
Leica Biosystems, Nussloch, Germany), which includes post
primary rabbit anti-mouse IgG antibody. K16 was detected with
rabbit anti-K16 antibody (0.5 mg/ml) (Cat no.:Ab76416, AbCam,
Cambridge, United Kingdom) and CD3 with rabbit anti-CD3
antibody (3 mg/ml) (Cat no.:A0452, Agilent, California, United
States). All the stains were performed with appropriate positive
and negative controls and isotype controls. A more detailed
description is included in the supplementary materials.
2.5. Protein analysis
Protein analysis was performed on both culture supernatants
and tissue lysates. The method for tissue lysis is described in
supplementary materials. The protein levels of IL-22 and IL-17F
were measured with ELISA, using Human IL-22 Quantikine ELISA
kit and Human IL-17F DuoSet ELISA Kit (both from R&D Systems).
The MSD platform (Meso Scale Discovery, Rockville, MD, USA) was
used for measuring IL-17A/F (U-PLEX biomarker Group 1 (hu)
Individual assay IL-17A/F), IL-4, IL-5, IL-13, TARC, IL-17A, IFN-g,
TNF-α, CCL-2 and IL-1α (Human U-PLEX), IL-8 (Human IL-8 (HA)
V-PLEX) and CCL-20 (Human Cytokine assay: Tissue culture kit,
CCL-20). All analyses were preformed according to the manufac-
turer’s instructions. Protein levels were quantified according to a
standard curve prepared using a similar skin matrix and expressed
in pg/ml. Protein levels from tissue lysates were adjusted for the
protein recovery efficiency.
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Total RNA was extracted by using the mirVana kit (Life
Technologies) according to the instructions provided by the
manufacturer and Precellys1 24 tissue homogenizer (Bertin
instruments, Montigny-le-Bretonneux, France) for the mechanical
lysing of the tissue. cDNA synthesis was performed with the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,Fig. 1. Co-localization of mouse anti-human CD3 and CD28 antibodies and T cells. Fu
48 h with addition of rhIL-23 and anti-CD3 and anti-CD28 or isotype control antibodies. 
point. A) IHC staining of isotype control treated samples targeting mouse IgG for detec
samples targeting mouse IgG for detection of anti-CD3 and anti-CD28 antibodies. C) IHC s
bars equal to 250 mm. One representative donor out of 4 is shown (n = 4).Foster City, CA). cDNA was amplified by quantitative real-time PCR
using Taqman1 Gene Expression Assays. (Assay IDs are listed in the
supplementary materials.)
2.7. Statistical analysis
Means and SEM are calculated from the repeated experiments.
Values are represented as relative gene expression, proteinll thickness punch biopsies were cultured in submerged conditions for 2, 5, 15, 24 or
The tissue was formalin fixed and paraffin embedded at each indicated culture time
tion of the isotype control. B) IHC staining of anti-CD3 and-CD28 antibody treated
taining of T cell stimulated samples targeting human CD3 for detection of T cells. The
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as percentage of the vehicle control (100 %) for each experiment.
By the use of GraphPad Prism software, statistical analysis was
performed with Wilcoxon signed-rank test (*P  0.05; **P  0.01,
***P  0.001, ****P  0.0001).
3. Results
3.1. In situ stimulation resumes T cell activity in ex vivo culture of
psoriatic skin
In the ex vivo culture of psoriatic keratome skin, T cell activity is
resumed by in situ T cell activation using anti-CD3 and anti-CD28
antibodies [12]. Therefore, we investigated, whether in situ
activation of the T cells in psoriatic full thickness punch biopsies
is feasible and necessary.
Firstly, the penetration and distribution of the T cell-activating
antibodies were addressed by culturing the biopsies in the
presence of rhIL-2 alone or with rhIL-2, rhIL-23, and mouse
anti-human CD3 and anti-human CD28 antibodies, or isotype
control (mouse IgG) for 2, 5, 15, 24 or 48 h. IHC analysis of tissue
stained with rabbit anti-mouse IgG clearly shows the presence of
mouse anti-human CD3 and CD28 antibody (Fig. 1, B) but not of
mouse isotype control antibody (Fig. 1, A) indicating that only T cell
stimulating antibodies (anti-human CD3 and CD28) were able to
distribute within the skin due to their high affinity to the targets.
The presence of mouse anti-human CD3 and CD28 was observed in
the samples already after the first 2 h of culture (Fig. 1, B).
Furthermore, the T cell stimulating antibodies were found to
co-localize with the T cell infiltrates in the tissue, as demonstrated
by the similar expression pattern of CD3 (Fig. 1, C).
Secondly, we investigated whether in situ T cell stimulation
results in functional T cell activation by following their capacity to
secrete proinflammatory cytokines. It was found that the level of
IL-17A released in the culture media was already increased after
15 h of culture, and being most prominent after 48 h compared to
both unstimulated and isotype treated controls (Fig. 2). SimilarFig. 2. IL-17A expression is increased by T cell stimulation after 15 h, 24 h and 48 h of
48 h with or without rhIL-23 and anti-CD28 and anti-CD3 antibodies or with rhIL-23 a
supernatants using MSD platform. The data was obtained for 4 different donors in oneresults were obtained for IL-22, IL-17F, IL-17A/F and IFN-g
(Supplementary, Figure S2). Undetectable or low levels of the
Th2 related cytokines IL-13, IL-5 and IL-4 and the chemokine TARC
were found in the tissue culture supernatants during the entire
culture period (Supplementary, Figure S3), indicating that the
psoriasis associated Th17 and Th1 phenotypes were maintained
during the culture.
Taken together, the in situ T cell stimulation with anti-CD3 and
anti-CD28 antibodies results in functional T cell activation and is
necessary for creating a window of expression, as demonstrated by
approximately 4-fold increase of IL-17A expression at 48 h of
culture in the stimulated samples, when compared to the isotype
control.
3.2. Maintenance of the psoriatic inflammatory phenotype and
histopathological features in prolonged culture
We confirmed that T cells can be activated by the exogenous in
situ activation and that the phenotype of the Th17 cells is
maintained for at least 48 h. Consequently, we further investigated,
whether the culture period can be prolonged beyond 48 h, and
whether the inflammatory profile of the model is comparable to
that of psoriasis lesions in vivo.
The tissue morphology and integrity was evaluated by HE
staining (Fig. 3, A). As an effect of the submerged culture
conditions, spongiosis of the tissue was detectable after 48 h of
culture manifested as swelling of the cells in the epidermis.
However, the overall tissue integrity was acceptable and main-
tained up to 96 h. At 144 h of culture, the tissue integrity was
clearly decreased, which was seen as pronounced detachment of
the epidermis from the dermis in some of the samples as well as
necrotic areas in the epidermis (Fig. 3, A, panel far right, black
arrow). However, the classical psoriatic features, such as epidermal
hyperplasia, parakeratosis and the elongation of rete ridges, were
maintained throughout the culture time. T cells were maintained
in the tissue at all the measured time points, as shown by the CD3
IHC staining (Fig. 3, B). Additionally, it was found that only a culture. The psoriatic full thickness punch biopsies were cultured for 2, 5, 15, 24 or
nd isotype control. The IL-17A protein levels were measured in the tissue culture
 experiment (n = 4). The dotted line indicates LLOQ. The error bars express  SEM.
Fig. 3. The tissue integrity and the psoriasis phenotype is maintained up to 96 h of culture. For the histological analysis full thickness punch biopsies were either
formalin fixed immediately after arrival to the laboratory (denoted as 0 h) or cultured in submerged conditions for 48 h, 96 h or 144 h with addition of rhIL-23 and anti-
CD3 and anti-CD28 antibodies. The tissue was formalin fixed and paraffin embedded in the end the culturing period. A) HE staining, B) IHC staining for CD3 C) IHC staining
for keratin 16. The bars equal to 250 mm. The results of one representative donor out of six is shown (n = 6). For the mRNA and protein analysis, 6 or 7 psoriatic full
thickness punch biopsies were obtained per donor. 1 biopsy was snap frozen immediately after isolation from the donor and the rest were cultured for 48, 96 or 144 h with
or without rhIL-23 and anti-CD28 and anti-CD3 antibody stimulation. The mRNA expression was measured in tissue lysates of the cultured and the snap frozen biopsies. D)
IL17A and F) IL8 mRNA expression was normalized to GAPDH, PGK1 and PPIA reference genes. The relative gene expression values  upper and lower limits are mean
values from independent experiments using skin samples from three different donors (n = 3). Protein levels of E) IL-17A and G) IL-8 were measured in tissue culture
supernatants and in tissue lysate of snap frozen biopsies (samples denoted as 0 h) using MSD platform. The samples were obtained from six different donors (n = 6) from
two independent experiments. The dotted line indicates LLOQ. The error bars express  SEM. Wilcoxon signed-rank test was used to compare the mRNA and protein
expression levels (****P  0.0001; ***P  0.001; **P  0.01).
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shown). Keratin 16 (K16) expression, a marker for keratinocyte
hyperproliferation, remained stable throughout the culture period,
as shown by the K16 IHC staining (Fig. 3, C). T cell stimulation did
not affect the tissue integrity, retainment of T cells in the tissue or
the expression of keratin 16. Finally, protein levels of IL-1α released
in the tissue culture supernatant were assessed to address signs ofcellular toxicity and irritation. The levels were found to be stable
throughout the culture time, and not affected by the T cell
stimulation (Supplementary, Figure S4).
To evaluate the inflammatory profile of the cultured skin, IL-17A
expression was measured in samples cultured with rhIL-2 and
either with or without the addition of rhIL-23, anti-CD3 and anti-
CD28 antibodies for 48, 96 and 144 h, and in tissue lysates prepared
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from the patient. For the cultured samples the IL-17A protein
expression was measured in the tissue culture supernatant and the
mRNA expression in the tissue. The in situ T cell stimulation
increased the expression of IL-17A at all the measured timepoints
both at the mRNA level (Fig. 3, D) and protein level (Fig. 3, E)
compared to unstimulated control, but the expression declined
during the culture time. Importantly, the secreted levels of IL-17A
in the supernatants were comparable to the levels detected in vivo.
Similarly, in situ T cell stimulation also increased the expression of
IL-17F, IL-17A/F, IL-22, and TNF-α compared to unstimulated
control (Supplementary, Figure S5). However, the protein levels of
IL-17F and IL-17A/F were approximately 5-fold higher in the ex vivo
culture setting compared to the levels detected in vivo (Supple-
mentary, Figure S5). Compared to the in vivo samples, the levels of
IL-22 secreted in the supernatant were initially higher after 48 h of
ex vivo culture, but similar after 96 and 144 h of culture
(Supplementary, Figure S5). The secreted level of TNF-α in the
culture media were approximately 6-fold lower compared to the in
vivo samples (Supplementary, Figure S5).
To examine whether the expression of keratinocyte-derived
chemokines is maintained during the culture period, and whether
the expression resembles the levels found in vivo in psoriasis, the
level of the IL-17A-induced chemokine, IL-8, was measured.
Compared to in vivo samples, the ex vivo T cell stimulation resulted
in an increased mRNA expression, whereas at the protein level IL-8
was found to be expressed in the same range in the tissue culture
supernatant as in vivo (Fig. 3, F and G). Further, the expression of
IL-8 was high and not further increased by the T cell stimulation at
any time point neither at protein level (Fig. 3, F) or mRNA level
(Fig. 3, G).
The induction of IL-17A, IL-17F, IL-17A/F, IL-22 and IFN-g
protein expression was investigated also without the exogenous
addition of rhIL-23. The expression of these cytokines could be
induced by stimulation with anti-CD3 and anti-CD28 antibodies
alone, but the addition of rhIL-23 further increased the expression.
The keratinocyte-derived chemokines CCL-20, CCL-2 and IL-8 were
not affected by the addition of rhIL-23 (Supplementary, Figure S6).
3.3. Translational and pharmacological evaluation of the model
Having established that the cultured tissue replicates the key
molecular and histopathological features of psoriasis inflamma-
tion and that the psoriasis phenotype can be sustained up to 96 h,
the feasibility of using this model for pharmacological studies was
also investigated.
Two types of treatment with different mechanisms of action
were tested. Betamethasone dipropionate (BDP), representing a
corticosteroid treatment, and a commercially available anti-IL-17A
antibody, representative of a biological treatment used in the
clinic, were applied in the beginning and throughout the culture
period. BDP decreased the protein levels of IL-17A (Fig. 4, A) and
mRNA levels of IL17A and DEFB4 (Fig. 4, B and C) after 96 h of
culture, compared to the vehicle control. Similar results were
found for IL-8, CCL-2, IFN-g, TNF-α and IL-22 (Supplementary,
Figure S7). The antibody treatment significantly inhibited the
protein expression of IL-8 (Fig. 4, D) and the mRNA expression of
both IL8 and DEFB4 after 96 h of culture, when compared to isotype
control (Fig. 4, E and F). Similar results were found for IL-17A, IL23A
and CXCL1 mRNA expression (Supplementary, Figure S8). It has
been previously shown that psoriatic keratinocytes express IL-23
[13,14]. Our results suggest that the downregulation of IL-23
expression in anti-IL-17A antibody treated samples could be due to
either direct or secondary effects by blocking IL-17 signalling in
keratinocytes. The level of IL-22 were not affected by anti-IL-17A
antibody treatment (Supplementary, Figure S8).4. Discussion
In order to understand how immunomodulatory drugs affect
the interplay between different cell types, and may improve
psoriasis, there is a need for translational models, where the
immunological events of psoriasis are well replicated. In our
model, full thickness punch biopsies of lesional psoriatic skin were
cultured under submerged conditions. Previously Lovato et al. [12]
described that T cells within keratome skin samples from psoriasis
patients need to be activated ex vivo in order to regain the
inflammatory activity as in vivo, and therefore rhIL-2, rhIL-23, anti-
CD3 and anti-CD28 antibodies were added to the culture medium.
In line with these findings, we showed that in situ stimulation of
skin T cells by the same stimulation cocktail as in the keratome
cultures resulted in a psoriasis-specific expression of proinflam-
matory cytokines maintained for up to 96 h of culture and at levels
comparable to the expression observed in vivo for most of the
cytokines. Also, the histopathological features of psoriasis were
retained and tissue integrity remained acceptable up to 96 h of
culture, altogether suggesting that the psoriasis inflammation and
psoriasis-like tissue morphology are maintained under the culture
conditions. The presence of these features is advantageous, since
they are rarely adequately achieved in in vitro models, such as
reconstructed skin models (reviewed in [9]).
Stimulation of T cells without addition of exogenous IL-23
resulted in an upregulation of several T cell-derived cytokines,
indicating that the model can be modified to specific needs, such as
for investigating the effect of treatments targeting the IL-23/IL-12
pathway. In fact, mRNA expression of IL-23 was found to be on par
with levels detected in vivo throughout the culture time
(Supplementary, Figure S9). However, as the biggest window for
investigating treatment effect on T cell activity is reached by
addition of IL-23, this approach is preferable for pharmacological
studies, whenever compatible.
We demonstrated the feasibility and relevance of the psoriasis
ex vivo culture as a model for pharmacological studies by testing
the effect of two treatments, with clinically validated targets, on
the expression of the key markers of psoriasis. The corticosteroid
treatment resulted in a significant decrease in both T cell-and
keratinocyte-derived soluble mediators, while the treatment with
an anti-IL-17A antibody resulted in an immunological modulation
of the cross-talk between T cells and keratinocytes with significant
inhibition of the expression of IL-8 and DEFB4. Of note, it is clear
from the data that the responses to in situ T cell activation and to
the two types of treatment are donor dependent. However, it is
important to keep in mind that the variation in the data reflects
what is also seen in clinical studies. As an example, the anti-IL-17A
antibody secukinumab downregulates the protein expression of
human beta defensin (hBD)-2 in psoriasis patients, but the
expression levels among individual patients vary broadly both
before and after treatment [15].
The keratinocyte-derived proinflammatory mediators were not
found to be affected by the T cell stimulation to the same extent
and were readily produced in the culture, suggesting that there is a
difference between keratinocytes and T cells in their activation
state. Reasons for this phenomenon are yet to be elucidated, but
the stimulation-independent expression of proinflammatory
mediators could be a response to the mechanical trauma induced,
when the biopsy is taken, or a response to the culture conditions, or
a combination of both. However, the keratinocyte responses were
T cell-dependent, since it was possible to downregulate the
expression of the keratinocyte-derived IL-8 significantly by
anti-IL-17A treatment.
The tissue integrity was acceptable at 96 h, but clearly
compromised at 144 h of culture. The histological observations
are supported by the finding that the expression of T cell-and
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culture. These results lead us to conclude that the reliability of
the model is sustained up to 96 h, whereas any results obtained on
a later time point should be critically reviewed. A culture time of
96 h is significantly shorter than what was reported previously by
Varani et al. [16] in a similar experimental set up, where psoriatic
full thickness biopsies were cultured for 8 days in submergedFig. 4. Treatment effect by betamethasone dipropionate and anti-IL-17A antibody. Fu
with or without addition of rhIL-23 and anti-CD3 and anti-CD28 antibodies. Betame
antibody or corresponding isotype control were added to the culture medium in the beg
tissue culture supernatant using MSD platform and the mRNA expression was measu
treatment with BDP, B) IL17A mRNA expression upon treatment with BDP, C) DEFB
treatment with anti-IL-17A antibody, E) IL8 mRNA expression upon treatment with an
antibody. The protein expression expressed as the percentage difference compared to
donors (n = 5) from three independent experiments. The mRNA expression of IL8 and
values  upper and lower limits are mean values from three independent experiments f
effect (****P  0.0001; ***P  0.001; **P  0.01; *P  0.05).conditions, but without exogenous T cell stimulation and in KBM
culture medium supplemented with 1.4 mM Ca2+. However, in that
study the characterization of the psoriasis phenotype was limited
to evaluation of the histological features of the tissue at day 0 and
8. Others have also reported the use of ex vivo culture of psoriasis
skin for testing effects of anti-inflammatory compounds [10,11].
However, in these studies characterization of the psoriasisll thickness punch biopsies were cultured in submerged conditions for 96 h either
thasone dipropionate BDP (1mM) or vehicle control (0.1 % DMSO) or anti-IL-17A
inning of the culture period. The levels of soluble mediators were measured in the
red in tissue lysates of the cultured biopsies. A) IL-17A protein expression upon
4 mRNA expression upon treatment with BDP, D) IL-8 protein expression upon
ti-IL-17A antibody, F) DEFB4 mRNA expression upon treatment with anti-IL-17A
 vehicle treatment control are the mean values  SEM measured in five different
 DEFB4 was normalized to GAPDH, PGK1 and PPIA. The relative gene expression
rom four different donors (n = 4). Wilcoxon signed-rank test was used to treatment
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time was shorter compared to our model, limiting the feasibility to
investigate effects by anti-inflammatory compounds [10,11]. On
the contrary, we demonstrated that the time frame in our model is
sufficient to see treatment effects of both a small molecule and an
antibody.
It is important to stress that the effects of submerged culture
conditions are not entirely known, and it can be assumed that it
affects the tissue integrity of the psoriasis skin negatively. Indeed,
several studies have been made to characterize healthy human
skin explants in culture, including commercially available models
like NativeSkin1 from Genoskin [17], where skin explants are
cultured at air-liquid interface and the tissue integrity is
maintained for a prolonged period of time [18–20]. A little light
is shed on this matter in the study by Peramo and Marcelo, 2012
[18], where full thickness biopsies of healthy human skin were
cultured either in a transwell system at air-liquid interface or semi-
submerged in the culture medium. They found that the tissue
integrity of biopsies cultured in submerged conditions declined
faster compared to the tissue cultured at air-liquid interface.
Interestingly, Companjen et al. [21] state that healthy skin
deteriorates slower compared to psoriatic skin, when cultured
at air-liquid interface, but the deterioration can be largely avoided
by culturing the psoriatic skin in an atmosphere containing 95 %
oxygen. These studies indicate that the model could potentially be
further optimized by air exposure, if a suitable technical setting can
be found for relatively small biopsies.
In conclusion, we present here a well-characterized model
using ex vivo culture of psoriasis full thickness biopsies. Although
one limitation of our model is the lack of feasibility to test topical
drugs as the skin samples are submerged in the culture media, we
provide a thorough characterization of its feasibility to maintain
psoriasis inflammatory responses and to be employed for
pharmacological studies as well as for elucidating the immuno-
pathological events of psoriasis.
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